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Background: Pegylated interferon combined with ribavirin treatment is an effective therapy for chronic hepatitis C
viral infection. However, pegylated interferon combined with ribavirin is associated with various adverse reactions.
Severe thrombocytopenia is a life-threatening side effect of interferon therapy that can lead to bleeding. It is
generally understood that the inosine triphosphatase-CC genotype does not have a significantly lower reduction
by pegylated interferon combined with ribavirin in the mean platelet counts compared with the AA/CA genotype. We
report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis C treated with pegylated
interferon combined with ribavirin in spite of having the inosine triphosphatase-CC genotype.
Case presentation: A 57-year-old female had been diagnosed as having HCV infection in 2008. The inosine
triphosphatase gene showed one single nucleotide polymorphism (rs1127354) C/C (major homozygous) and the IL28B
gene showed single nucleotide polymorphism (rs8099917 T/T, rs11881222 T/T) (major homozygous). The patient was
treated with pegylated interferon 180 μg once a week combined with ribavirin 600 mg per day from April 2011. The
hepatitis c virus ribonucleic acid turned negative 9 weeks after treatment with pegylated interferon combined
with ribavirin. During the therapy, the platelet count remained above 8.0 × 104/μl for about 9 months. In January
2012, the platelet count was 6.8 × 104/μl. In February 2012, the 44th week from the beginning of the treatment,
a sudden decrease in the platelet count to 0.8 × 104/μl was observed. After prednisolone was administered, the
platelet count increased. Finally the platelet count had risen above normal range.
Conclusion: We should pay careful attention in the differential diagnosis for patients with the inosine
triphosphatase-CC genotype because, although rare, severe thrombocytopenia could occur.
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Chronic infection with hepatitis C virus (HCV) affects
up to 170 million individuals worldwide [1] and may
lead to progressive hepatic fibrosis and cirrhosis, with
risk of liver failure and hepatocellular carcinoma.
Pegylated interferon (PEG-IFN) combined with ribavirin
(RBV) treatment (PEG-IFN/RBV) is an effective therapy
for chronic HCV infection. However, PEG-IFN/RBV is* Correspondence: hisashi7@kitasato-u.ac.jp
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reproduction in any medium, provided the orassociated with various adverse reactions. Some of these
side effects are mild, such as flu-like symptoms. Some
others can be very severe and even lead to lethal conse-
quences [2]. Severe thrombocytopenia is a life-threatening
side effect of interferon therapy that can lead to bleeding,
and even death, if diagnosis and treatment are not ad-
equately given. Therefore, how to identify the possibility
of thrombocytopenia early is critical for patients treated
with PEG-IFN/RBV.
Recently, genome-wide association studies have identi-
fied that the genetic variant of rs1127354 single nucleo-
tide polymorphisms (SNPs) in the inosine triphosphatasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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osine triphosphate (ITP), has been found to be associated
with thrombocytopenia. The ITPA-AA/CA genotype was
independently associated with a higher degree of reduction
in platelet counts at 4 weeks as well as protection against
the reduction of hemoglobin in patients treated with PEG-
IFN/RBV [3-5], while the CC genotype had significantly
lower reduction in the mean platelet counts compared with
the AA/CA genotype [5]. Here, we report a case of severe
thrombocytopenia that developed in a patient with chronic
hepatitis C treated with PEG-IFN-α2a plus ribavirin in spite
of having the ITPA-CC genotype.
Case presentation
A 57-year-old female had been diagnosed as having
HCV infection in 2008 in another hospital. Laboratory
test showed that her serum and anti-HCV, and HCV
ribonucleic acid (RNA) were positive in October 2010 at
Kitasato University East Hospital. The patient’s labora-
tory findings prior to receiving treatment, in March
2011, are shown in the Table 1. The ITPA gene showed
one single nucleotide polymorphism (SNP) (rs1127354)
C/C (major homozygous) and the IL28B gene showed
SNP (rs8099917 T/T, rs11881222 T/T) (major homozy-
gous) [5].
She had a history of a little alcohol consumption and
of smoking 20 cigarettes per day for longer than 30 years.
Her height was 156.3 cm, and her body weight was
57.5 kg. Her mother had a history of hypertension. The
patient had no history of ever having a blood transfu-
sion. The ultrasonographic examination showed that the
patient’s liver, spleen, and pancreas were normal, but sheTable 1 The patient’s laboratory findings prior to
receiving treatment
WBC 5800 /μL CRP <0.10 mg/dl
RBC 404 × 104 /μL LDH 238 U/L
Hb 13.5 g/dL UA 5.8 mg/dL
Plt 16.7 × 104 /μL BUN 12.6 mg/dL
PT 11.7 sec Cr 0.52 mg/dL
AST 41 IU/L Na 141 mEq/l
ALT 46 IU/L K 3.8 mEq/l -
TP 7.6 g/dL HBsAg (−) -
Alb 4.4 g/dL HCVAb (+) -
TBIL 0.5 mg/dL HCV-RNA 6.3 LogIU/ml
ALP 248 IU/L Genotype 1B
γ-GTP 20 IU/L
WBC, white blood cells; RBC, red blood cells; Plt, platelets; PT, prothrombin
time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TP, total
protein; Alb, albumin; TBIL, total bilirubin; ALP, alkaline phosphatase; γ-GTP,
gamma glutamyl transpeptidase; CRP, C-reactive protein; LDH, lactate dehydro-
genase; UA, uric acid; BUN, blood urea nitrogen; Cr, creatinine; Na, natrium; K,
potasium; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus antibody;
HCV-RNA, hepatitis C virus ribonucleic acid.had gallstones. The liver biopsy revealed chronic active
hepatitis (fibrosis grade 3 and inflammatory activity
grade 1) in the Metavir classification and a hepatic activ-
ity index score of 1-1-3-3 (Figure 1).
The patient was treated with PEG-IFN-α-2a 180 μg
once a week combined with ribavirin 600 mg per day
from April 2011. The HCV RNA turned negative 9 weeks
after treatment with PEG-IFN-α-2a. During the therapy,
the platelet count remained above 8.0 × 104/μl for about
9 months. In January 2012, the platelet count was 6.8 ×
104/μl. In February 2012, the 44th week from the begin-
ning of the treatment, a sudden decrease in the platelet
count to 0.8 × 104/μl was observed (Figure 2). Severe
thrombocytopenia caused by the PEG-IFN-α-2a therapy
was suspected. Therefore, the PEG-IFN-α-2a and ribavi-
rin were discontinued. The patient was then admitted to
our hospital.
On admission, the blood pressure, temperature and
pulse of the patient were normal. Her white blood cell
and neutrophil values were also in the normal range.
And there was no evidence of bacterial, viral, or other
microorganism infection. Purpura were noted on both
lower limbs and her trunk. The white blood cell count
was 3000/μl, the red blood cell count was 3.14 × 106/μl,
hemoglobin was 11.2 g/dl, but the platelet count had de-
creased to 1.1 × 104/μl. The liver function and coagula-
tion function were normal. But the PAIgG was elevated
to 180 ng/L (normal range, 9-25 ng/L).
A bone marrow aspiration examination was performed
to investigate the etiology of the thrombocytopenia. The
specimen revealed that there was hypoplasia of myelo-
cytes (especially in megakaryocytes) but no myeloblasts,
which did not suggest any evidence of bone marrow dis-
ease (Figure 3).
Based on these results, she was diagnosed as having
immune-mediated thrombocytopenia caused by the PEG-
IFN-α-2a therapy. Therefore, the PEG-IFN/RBV was dis-
continued, but the platelet count remained below 1.0 × 104/
μl. We confirmed that her anti-Helicobacter pylori was
positive but did not perform eradication therapy. In March
2012, 60 mg of prednisolone were administered orally.
After starting corticosteroid therapy, the platelet count
increased gradually. Then the prednisolone was gradually
tapered down by 10 mg every 4 days, the platelet count
gradually rose above 10 × 104/μl, and the PAIgG was
decreased to 80 ng/L. When the prednisolone dosage
decreased to 30 mg per day orally, she was discharged.
The prednisolone was gradually tapered off, and the
platelet count returned to normal (Figure 2). Prednis-
olone was discontinued in May 2012. Her platelet
count remained normal during the follow-up. And
HCV RNA has never been detected since. She was di-
agnosed as having a sustained virologic response (SVR)
6 months later.
Figure 1 Liver biopsy (A: Hematoxylin and Eosin stain × 100; B: Masson trichrome stain × 100): fibrosis grade 3 and inflammatory
activity grade 1 in the Metavir classification, Histologic activity index score: 1-1-3-3.
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To our knowledge, this is the first case report to assess
the relationship between severe thrombocytopenia that
developed in a patient treated with PEG-IFN/RBV and
that patient having the ITPA genotype. It is a worthwhile
case because, in spite of having the ITPA-CC genotype,
the patient developed severe thrombocytopenia caused
by the PEG-IFN/RBV treatment.
It is generally thought that an ITPA genetic variant is
independently associated with reduction in the mean
platelet counts for weeks 2, 4, 8, and 12 [5]; while it is
also associated with the reduction of hemoglobin for
those same weeks caused by the RBV [5]. On the other
hand, IL28B genetic variant strongly associated with the
response to PEG-IFN/RBV [6]. Patients with the IL28-
TT genotype exhibit higher prevalence of virologic re-
sponse compared to those with IL28B-TC/CC [6]. When
we began to administer the PEG-IFN/RBV treatment, weFigure 2 Clinical course of the patient.expected the possibility of SVR and had been cautious of
the reduction of hemoglobin because the patient had the
IL28B-TT and ITPA-CC genotypes. Indeed, she achieved
negative HCV RNA after only 9 weeks administration of
PEG-IFN/RBV and her hemoglobin level had gradually
decreased to a maximum of 9.6 g/dl. The side effects of
PEG-IFN/RBV treatment are widely known, such as
leukopenia, anemia, and thrombocytopenia. Hematologic
abnormalities often lead to dose reduction and premature
withdrawal from therapy in 10%–14% of patients [7]. It is
not rare that mild-to-moderate thrombocytopenia is caused
by PEG-IFN/RBV, and it has been attributed to a direct in-
hibition of stem cell proliferation and differentiation in the
bone marrow [8]. Yamane et al. reported IFN-α directly
inhibited cytoplasmic maturation and platelet productionFigure 3 Bone marrow specimen (May-Geimsa stain × 400):
The specimen showed myelocyte hypoplasia, especially in
megakaryocyte, and no atypical cells.
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megakaryocytes [9]. However, severe thrombocytopenia
(platelet counts less than 2.5 × 104/mm3) during interferon
therapy is rare, and it is a life-threatening side effect.
In the present case, in the early period of administra-
tion (within 12 weeks) of PEG-IFN/RBV, mild-to-
moderate thrombocytopenia was caused by the treatment,
but the platelet count remained at or around 10 × 104/μl
for 9 months. Li et al. reported in their review of severe
thrombocytopenia induced by IFN-α in 17 patients [10]
that the median onset time from the administration of
IFN-α/PEG-IFN-α treatment was 3.6 months (range,
1–36 months), and the patients could recover by dis-
continuing the IFN-α/PEG-IFN-α and administering
an immunosuppressant. It is noteworthy that they re-
ported that 16 patients (94%) had reached SVR in spite
of a short period of IFN-α administration. Generally,
PEG-IFN/RBV can achieve rates of an SVR of less than
50% in patients with HCV genotype 1 [2]. Therefore, there
might be a correlation between severe thrombocytopenia
and SVR that is caused by PEG-IFN/RBV therapy.
It is necessary to consider the mechanism in the present
case of this severe thrombocytopenia. The IFN-α treatment
is considered an immune-modulator and increases the risk
for immune thrombocytopenia purpura in patients with
hepatitis C [10], but the mechanism of IFN-induced auto-
immune thrombocytopenia is unclear [10]. IFN-α/PEG-
IFN-α can induce the production of autoantibody against
thrombocytes, such as platelet antibody, which can lead to
immune-mediated thrombocytopenia [11]. This situation is
critical and may sometimes result in death. IFN can en-
hance the expression of major histocompatibility class I an-
tigens and promote the production of IL-1 (interleukin 1)
and TNF-α (tumor necrosis factor alpha). The over expres-
sion of these cytokines can induce autoimmune disease
[12]. It is observed that higher Th1 (T helper 1) cell reactiv-
ity with platelets is related to idiopathic thrombocytopenic
purpura (ITP) patients. PEG-IFN can increases IFN-γ se-
cretion and improve CD4 T cell response in HCV-infected
patients [13]. This may be one of the reasons of
autoimmune thrombocytopenia during PEG-IFN treat-
ment [14]. Recently, it is considered that autoimmune
thrombocytopenia is associated with imbalance of Treg/
Th17 cells [15]. But, to our knowledge, there are no data in
PEG-IFN induced thrombocytopenia.
Regarding the treatment, we discontinued PEG-IFN/
RBV after we diagnosed IFN-induced autoimmune
thrombocytopenia and administrated 60 mg of pred-
nisolone first. Li et al. reported that early administra-
tion of immunosuppressant was an effective therapy
for IFN-α induced severe thrombocytopenia [10].
Finally, it was considered that this case was “possible”
drug-induced immune thrombocytopenia based on cri-
teria and level of evidence for establishing a causativerelationship in drug-induced thrombocytopenic purpura by
George et al. [16,17]. It is the reason that this case meets
only their first criteria and evidence: therapy with the candi-
date drug preceded the thrombocytopenia, and recovery
from thrombocytopenia was complete and sustained after
discontinuation of therapy.
The 2011 practice guideline by the AASLD (American
Association for the Study of Liver Diseases) recommended
that IL28B genotype variants are robust pretreatment predi-
cators of the SVR to PEG-IFN/RBV in patients with geno-
type 1 chronic HCV infection [1]. In thrombocytopenia
caused by PEG-IFN/RBV, there is a tendency that patients
with the ITPA-CC genotype are considered to be less at risk
than those with the ITPA-CA/AA genotype. However, the
newest treatment (PEG-IFN/RBV and protease inhibitors)
might weaken this tendency. Therefore, this case of severe
thrombocytopenia that developed in a patient with chronic
hepatitis C treated with PEG-IFN/RBV in spite of the pa-
tient having the ITPA-CC genotype should be kept in mind.
Conclusion
In conclusion, it is generally understood that the CC geno-
type had significantly less reduction in the mean platelet
counts compared with the AA/CA genotype. However, we
should pay careful attention in the differential diagnosis for
patients with the ITPA-CC genotype because, although
rare, severe thrombocytopenia could occur.
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